EA201791775A1 - Цистеиновая протеаза - Google Patents

Цистеиновая протеаза

Info

Publication number
EA201791775A1
EA201791775A1 EA201791775A EA201791775A EA201791775A1 EA 201791775 A1 EA201791775 A1 EA 201791775A1 EA 201791775 A EA201791775 A EA 201791775A EA 201791775 A EA201791775 A EA 201791775A EA 201791775 A1 EA201791775 A1 EA 201791775A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igg
proteasis
cytestine
vivo
methods
Prior art date
Application number
EA201791775A
Other languages
English (en)
Other versions
EA035896B1 (ru
Inventor
Кристиан Челльман
София Ярнум
Эмма Нордаль
Original Assignee
Ханса Медикал Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханса Медикал Аб filed Critical Ханса Медикал Аб
Publication of EA201791775A1 publication Critical patent/EA201791775A1/ru
Publication of EA035896B1 publication Critical patent/EA035896B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к новому полипептиду, который проявляет активность цистеиновой протеазы в отношении IgG, и к его применению in vivo и ex vivo. Применение полипептида включает способы профилактики или лечения заболеваний и состояний, опосредуемых IgG, и способы анализа IgG.
EA201791775A 2015-02-12 2016-02-12 Цистеиновая протеаза EA035896B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053054 WO2016128559A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (2)

Publication Number Publication Date
EA201791775A1 true EA201791775A1 (ru) 2018-02-28
EA035896B1 EA035896B1 (ru) 2020-08-27

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791775A EA035896B1 (ru) 2015-02-12 2016-02-12 Цистеиновая протеаза

Country Status (28)

Country Link
US (3) US10758597B2 (ru)
EP (2) EP3256579B1 (ru)
JP (1) JP6879921B2 (ru)
KR (1) KR102524594B1 (ru)
CN (2) CN113564150A (ru)
AU (1) AU2016217801B2 (ru)
BR (1) BR112017017286A2 (ru)
CA (1) CA2976016C (ru)
CL (1) CL2017002066A1 (ru)
CO (1) CO2017009060A2 (ru)
DK (1) DK3256579T3 (ru)
EA (1) EA035896B1 (ru)
ES (1) ES2962794T3 (ru)
FI (1) FI3256579T3 (ru)
GB (1) GB201502305D0 (ru)
HR (1) HRP20231496T1 (ru)
HU (1) HUE064122T2 (ru)
IL (1) IL253939B (ru)
LT (1) LT3256579T (ru)
MX (1) MX2017010389A (ru)
MY (1) MY187486A (ru)
PL (1) PL3256579T3 (ru)
PT (1) PT3256579T (ru)
RS (1) RS64840B1 (ru)
SG (1) SG11201706349YA (ru)
SI (1) SI3256579T1 (ru)
WO (1) WO2016128559A1 (ru)
ZA (1) ZA201705114B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3894571A4 (en) * 2019-01-28 2022-09-14 Duke University COMPOSITIONS AND METHODS FOR ESCAPING HUMOR IMMUNITY
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
MX2022004352A (es) 2019-10-17 2022-07-19 Stridebio Inc Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
MX2021014863A (es) 2019-12-06 2022-09-28 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022009065A (es) * 2020-01-22 2022-09-23 Spark Therapeutics Inc Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genica y para eliminar o reducir inmunoglobulinas.
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
WO2021244628A1 (zh) 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
US20230374083A1 (en) * 2020-09-21 2023-11-23 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof
AU2021358957A1 (en) 2020-10-07 2023-06-08 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965A1 (fr) * 2021-08-05 2023-02-10 Mc Saf Conjugués anticorps-médicament
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
WO2023084095A2 (en) 2021-11-15 2023-05-19 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
ATE398677T1 (de) 2000-12-21 2008-07-15 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN105770871A (zh) * 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
EP2190984B1 (en) 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
US20110020403A1 (en) * 2007-12-13 2011-01-27 Bengt Guss immunizing composition
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
SG173589A1 (en) 2009-02-09 2011-09-29 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
CN103068838B (zh) 2010-05-26 2016-03-02 英特瓦克公司 基于重组蛋白的抗链球菌感染疫苗
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Also Published As

Publication number Publication date
BR112017017286A2 (pt) 2018-04-17
AU2016217801A1 (en) 2017-08-10
US20180037962A1 (en) 2018-02-08
EP3256579B1 (en) 2023-08-30
RS64840B1 (sr) 2023-12-29
CO2017009060A2 (es) 2018-01-16
FI3256579T3 (fi) 2023-11-13
GB201502305D0 (en) 2015-04-01
JP2018510622A (ja) 2018-04-19
HRP20231496T1 (hr) 2024-03-01
IL253939B (en) 2020-01-30
US11524057B2 (en) 2022-12-13
MY187486A (en) 2021-09-24
EP3256579A1 (en) 2017-12-20
EA035896B1 (ru) 2020-08-27
PT3256579T (pt) 2023-11-23
CN107532158A (zh) 2018-01-02
KR102524594B1 (ko) 2023-04-21
ZA201705114B (en) 2024-01-31
US10758597B2 (en) 2020-09-01
SI3256579T1 (sl) 2024-01-31
ES2962794T3 (es) 2024-03-21
CA2976016C (en) 2023-08-29
MX2017010389A (es) 2017-12-07
KR20170110153A (ko) 2017-10-10
WO2016128559A1 (en) 2016-08-18
US20200179497A1 (en) 2020-06-11
CN113564150A (zh) 2021-10-29
CA2976016A1 (en) 2016-08-18
PL3256579T3 (pl) 2024-02-26
EP4265719A1 (en) 2023-10-25
LT3256579T (lt) 2023-11-27
US20230302100A1 (en) 2023-09-28
AU2016217801B2 (en) 2022-03-17
HUE064122T2 (hu) 2024-03-28
CL2017002066A1 (es) 2018-02-02
SG11201706349YA (en) 2017-09-28
JP6879921B2 (ja) 2021-06-02
DK3256579T3 (en) 2023-11-20
IL253939A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
EA201791775A1 (ru) Цистеиновая протеаза
EA201791773A1 (ru) Цистеиновая протеаза
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201790413A1 (ru) Антитела против tigit
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201691541A1 (ru) Новые анти-baff антитела
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201791467A1 (ru) Водный офтальмологический раствор
BR112017015880A2 (pt) anticorpos, usos e métodos
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201791937A1 (ru) Противовоспалительные полипептиды
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM